Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR

Journal of Pathology

Volumn 185, Issue 1, 1998, Pages 25-31

  Biesterfeld, Stefan ^a   Klüppel, Dominik ^a   Koch, Ralf ^a   Schneider, Susanne ^a   Steinhagen, Gerrit ^a   Mihalcea, Ana Maria ^a   Schröder, Willibald ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Breast cancer; Image analysis; Immunohistochemistry; MIB 1; Oestrogen receptor; PCNA; Progesterone receptor.; Survival rate

Indexed keywords

CYCLINE; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; OBSERVER VARIATION; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 2642671121     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199805)185:1<25::AID-PATH40>3.0.CO;2-R     Document Type: Article

References (42)

1. Bravo R, Frank R, Blundell PA, MacDonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase delta. Nature 1987; 326: 515-517.
2. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab J, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki67. J Immunol 1984; 133: 1710-1715.
3. Jain S, Filipe MI, Hall PA, Waseem N, Lane DP, Levison DA. Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol 1991; 44: 655-659.
4. Yonemura Y, Kimura H, Fushida S, et al. Analysis of proliferative activity using anti-proliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy. Cancer 1993; 71: 2448-2453.
5. Maeda K, Chung YS, Onoda N, et al. Proliferating cell nuclear antigen labelling index of preoperative biopsy specimens in gastric carcinoma with special reference to prognosis. Cancer 1994; 73: 528-533.
6. Kawai T, Suzuki M, Kono S, et al. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Correlation with DNA flow cytometric analysis. Cancer 1994; 74: 2468-2475.
7. Delahunt B, Bethwaite PB, Nacey JN, Ribas JL. Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: comparison with tumour grade, mitotic index, and silver staining nucleolar organizer region numbers. J Pathol 1993; 170: 471-477.
8. Kitamoto M, Nakanishi T, Kira S, et al. The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer 1993; 72: 1859-1865.
9. de Melo N, Matutes E, Cordone I, Morilla R, Catovsky D. Expression of Ki-67 nuclear antigen in B and T cell lymphoproliferative disorders. J Clin Pathol 1992; 45: 660-663.
10. Haapasalo HK, Sallinen PK, Helen PT, Rantala IS, Helin HJ, Isola JJ. Comparison of three quantitation methods for PCNA immunostaining: applicability and relation to survival in 83 astrocytic neoplasms. J Pathol 1991; 171: 207-214.
11. Sallinen PK, Haapasalo HK, Visakorpi T, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 1994; 174: 275-282.
12. Scotlandi K, Serra M, Manara MC, et al. Clinical relevance of Ki-67 expression in bone tumors. Cancer 1995; 75: 806-814.
13. Ramael M, Jacobs W, Weyler J, et al. Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). J Pathol 1994; 172: 247-253.
14. Oda Y, Hashimoto H, Takeshita S, Tsuneyoshi M. The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. Cancer 1993; 72: 478-485.
15. Sahin AA, Ro J, Ro JY, et al. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 1991; 68: 549-557.
16. Aaltomaa S, Lipponen P, Syrjänen K. Proliferating cell nuclear antigen (PCNA) immunolabelling as a prognostic factor in auxiliary lymph node negative breast cancer. Anticancer Res 1993; 13: 533-538.
17. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L, von Smitten K. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 1993; 68: 579-583.
18. Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker MIB-1. Gynecol Oncol 1995; 57: 96-104.
19. Jensen V, Ladekarl M, Holm Nielsen P, Melsen F, Soerensen FB. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol 1995; 176: 343-352.
20. Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 1990; 50: 7057-7061.
21. Soreide JA, Lea OA, Kvinnsland S. Cytosol protein content and prognosis in operable breast cancer. Correlations with steroid hormone receptors and other prognostic factors. Breast Cancer Res Treat 1991; 20: 25-32.
22. Joensuu HH, Toikkanen S. Identification of subgroups with favorable prognosis in breast cancer. Acta Oncol 1992; 31: 293-301.
23. Nomura Y, Miura S, Koyama H, et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. A univariate and multivariate analysis of 3089 Japanese patients with breast cancer from the Study Group for the Japanese Breast Cancer Society on Hormone Receptors and Prognosis in Breast Cancer. Cancer 1992; 69: 153-164.
24. Molino A, Turazza M, Bonetti A, et al. Estrogen and progesterone receptors in breast cancer: correlation with clinical and pathological features with prognosis. Oncology 1992; 49: 82-88.
25. Heise E, Gorlich M. Estradiol receptor and prognosis in human breast cancer and its metastases. Neoplasma 1993; 40: 55-57.
26. Gotteland M, May E, May Levin F, Contesso G, Delarue JC, Mouriesse H. Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents. Cancer 1994; 74: 864-871.
27. Kommoss F, Pfisterer J, Idris T, et al.Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short term prognosis. Anal Quant Cytol Histol 1994; 16: 203-210.
28. UICC (Union Internationale contre le Cancer) TNM. Klassifikation maligner Tumoren. Berlin: Springer-Verlag, 1987.
29. Bloom HJG, Richardson WH. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-377.
30. Müller HW, Böcking A, Auer H. TV cytometer CM-1 for computer aided tumor diagnosis. In: Wied GL, Bartels PH, Rosenthal DL, Schenck U, eds. Compendium of the Computerized Cytologic and Histologic Laboratory. Tutorials of Cytology. Chicago: 1994; 376-388.
31. Biesterfeld S, Striepecke E, Auer H, Böcking A. Single cell based quantification of the proliferation fraction by image cytometry. Virchows Arch 1995; 427: 339.
32. Biesterfeld S, Striepecke E, Manegold E, Handt S. Immunohistometry - an image analytical application for the single-cell based quantification of nuclear immunostaining. Electr J Pathol Histol 1995; 1: 954-03.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
34. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187-220.
35. Layfield LJ, Kerns BJM, Conlon DH, Inglehart JD, Marks JR, Dodge RK. Determination of proliferation index by MIB-1 immunostaining in early stage breast cancer using quantitative image analysis. Breast J 1995; 1: 362-371.
36. Sullivan RF, Mortimer G. Value of PCNA and Ki67 staining in breast cancer. J Clin Pathol 1993; 46: 188-189.
37. Thomas M, Noguchi M, Kitagawa H, Kinoshita K, Miyazaki I. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol 1993; 46: 525-528.
38. Cummings MC, Furnival CM, Parsons PG, Townsend E. PCNA immunostaining in breast cancer. Auz NZ J Surg 1993; 63: 630-636.
39. Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994; 57: 822-829.
40. Magno WB, Hirschfield L, Bhuiya T, Harrison T, Mir R. Correlation of proliferative index (PCNA reactivity and Ki-67 reactivity) in primary breast carcinoma with hormone status, lymph node status, and disease-free survival. Conn Med 1992; 56: 667-669.
41. Schönborn I, Minguillon C, Möhner M, Eberling K. Die Bedeutung der PCNA-Proliferationsfraktion und histomorphologischer Prognosefaktoren für das Ûbberleben beim Mammakarzinom. Pathologe 1993; 14: 307-312.
42. Schönborn I, Minguillon C, Lichtenegger W, Zschiesche W, Spitzer E. C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer. Geburtschilfe Frauenheilkd 1995; 55: 566-571.